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Curcumin: Synthesis optimization and in silico interaction
with cyclin dependent kinase
Curcumin is a natural product with enormous biological 
potential. In this study, curcumin synthesis was revisited 
using different reaction solvents, a catalyst (n-butylamine) 
and a water scavenger [(n-BuO)3B], to develop the optimal 
procedure for its rapid acquisition. During synthesis, sol-
vent choice was found to be an important parameter for 
better curcumin yield and high purity. In a typical reaction, 
acetyl acetone was treated with boron trioxide, followed by 
condensation with vanillin in the presence of tri-n-butyl 
borate as water scavenger and n-butylamine as catalyst at 
80 °C in ethyl acetate to afford curcumin. Moreover, cur-
cumin was also extracted from turmeric powder and spec-
troscopic properties such as IR, MS, 1H NMR and 13C NMR 
with synthetic curcumin were established to identify any 
impurity. The purity of synthetic and extracted curcumin 
was also checked by TLC and HPLC-DAD. To computation-
ally assess its therapeutic potential against cyclin depen-
dent kinases (CDKs), curcumin was docked in different 
isoforms of CDKs. It was observed that it did not dock at 
the active sites of CDK2 and CDK6. However, it could enter 
into weak interactions with CDK4 protein.
Keywords: curcumin synthesis, CDKs, molecular docking
Curcumin (C) is a phenolic compound that is considered to be a bioactive component 
of turmeric. Since ancient times it has been an integral part of ancient herbal medicine. 
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exists in keto and enol tautomeric forms due to intra-molecular hydrogen bonding be-
tween keto carbonyl oxygen and an enolic hydrogen atom (1). Possible therapeutic poten-
tial of curcumin was revealed in the last decades. Different studies have explained its ef-
ficacy against various types of cancers such as chemo resistant colon cancer cells, 
esophageal cancers, thyroid carcinomas, skin cancer (2) and as a potent anti‑inflammatory 
agent (3). Curcumin regulates various growth factors, protein kinases, inflammatory cyto-
kines and transcription factors to suppress the metastases and proliferation of human 
tumors (4). Other than anticancer and antitumor activities, it has also shown its effects 
against a variety of diseases such as respiratory tract infection, hepatic steatosis, skin pho-
toageing, Parkinson’s disease, pathogenesis of obesity, diabetes, HIV-associated diarrhea 
and Alzheimer’s disease, through inhibition of amyloid beta oligomer formation (5–8). The 
structure‑activity relationship studies of curcumin molecule against different biological 
targets have indicated that the presence of two phenyl rings with a C-7 linker with keto-
enol function (C=O groups as hydrogen acceptors and C-4 as a hydrogen donor) are most 
important for its biological activities. However, unsaturation in the linker (conformational 
flexibility) is important for its antitumor/anticancer activity but not for redox regulatory or 
apoptotic activities (9). Synthetic methodology to produce curcumin from acetyl acetone 
and 4-hydroxy-3-methoxybenzaldehyde (vanillin) has been reported, but these methods 
require a long reaction time and give a typical low yield over 3–4 steps of the synthesis 
procedure (10). Therefore, a more efficient and concise method is needed to prepare cur-
cumin in a short time.
Curcumin binds to different targets of cancer pathways, including protein kinases. It 
inhibits the activity of protein kinase C by forming hydrogen bonds with Leu 251 and Gln 
257 (PKC) in the C1B subdomain. It also optimally fits within the binding pocket of glyco-
gen synthase kinase-3b via attractive interactions with Val‑135, Ile‑62 and Arg‑141 (11). 
Curcumin is also reported to be a non-comparative inhibitor of phosphorylase kinase. Dif-
ferent CDKs are known as cancer targets and some of them have an established role in the 
onset of cancer (12). CDK1, CDK2 and CDK4/CDK6 play an important role in regulation of 
the cell cycle. Any irregularity in the activities of these CDKs may lead to the development 
of cancer. To our best knowledge, there is no information about the binding of curcumin 
with CDKs. In order to study the binding of curcumin with CDK, molecular docking stud-
ies were carried out with the primarily aim of predicting if there are any interactions be-
tween curcumin and CDKs and, secondly, to get an idea for designing a curcumin-based 
novel derivative for its better interaction with CDKs.
EXPERIMENTAL
Curcumin synthesis
Curcumin synthesis was performed according to ref. 10 with slight modifications. 
Acetyl acetone (1.03 mL, 10 mmol) and boric anhydride (0.35 g, 5.0 mmol) were dissolved 
in ethyl acetate (30 mL), and vanillin (3.04 g, 20 mmol) and tributyl borate (10.8 mL, 40 
mmol) were added. The reaction mixture was stirred at 80 °C for 30 min and then n-butyl-
amine (0.4 mL, 5.0 mmol) in ethyl acetate (5 mL) was added dropwise over 30 min and the 
mixture was stirred for 4 h at 80 °C. The progress of the reaction was monitored by TLC 
analysis. Upon complete consumption of the starting material, hydrochloric acid (1 mol 
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L–1) was added and the mixture was stirred. Organic layers of water-immiscible solvents 
were separated and extracted with an appropriate solvent. The combined organic layer 
was washed with water. The organic layer was dried over sodium sulfate, filtered and 
concentrated under reduced pressure. The crude product was recrystallized from metha-
nol to give curcumin as a yellow solid. The synthesis route is given in Scheme 1.
Extraction, isolation and purification of curcumin from turmeric
Curcumin was extracted from turmeric powder along with other curcuminoids (de-
methoxycurcumin, DMC, and bis‑demethoxycurcumin, BDMC) using 95 % ethanol at 
room temperature. Finally, the curcuminoid mixture was precipitated with petroleum 
ether. Various solvent systems including dichloromethane, ethyl acetate, benzene, chloro-
form, toluene and methanol were used to identify curcuminoids in the mixture by thin-
layer chromatography (TLC silica gel 60 F254, Merck, Germany).
Chloroform/methanol system was the best eluting agent to fractionate curcuminoids 
from the crude mixture using silica gel 60G column chromatography (Merck). First, elution 
with chloroform was carried out, and then polarity was increased by the chloroform/
methanol system to separate all fractions.
Curcumin characterization
In the present study, purity of synthesized and extracted curcumin was verified by 
the melting point, TLC, HPLC, IR, MS and NMR analyses. An Alpha IR spectrometer 
(FTIR‑ATR, Bruker, USA) and NMR spectrometer (Bruker) were used to record the IR and 
1H NMR (500 MHz) and 13C NMR (125 MHz) spectra, respectively, while the melting point 
was measured with a Gallenkamp apparatus (Gallenkamp and Co, UK). NMR spectra 
were recorded in DMSO‑d6. A JEOL MS 600H‑1 spectrometer (Jeol, Japan) with an electron 
spray ionization (ESI) interface was used for recording mass spectra.
HPLC Shimadzu Nexera X2 (Shimadzu, Japan) was equipped with a diode array de-
tector and DGU‑20A5 degasser (online), a variable volume loop injection valve and Phe-
Scheme 1
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nomenex Luna NH2 column (250 mm × 4.6 mm, 5.0-μm particle size) and was used at 25 
°C. Mobile phase comprised ethanol/water (85:15, V/V), the flow was set at 1.0 mL min–1 and 
elution followed at 425 nm. The Shimadzu LC program, LabSolutions analysis data sys-
tem, was used for integration of peak areas.
All solutions were filtered through a 0.45‑µm nylon filter and sonicated before injec-
tion into the chromatographic system. The sonicator used was from Fischer Scientific, UK.
Molecular docking and software
Molecular docking studies provided an insight into optimal matching between pro-
teins and other interacting molecules. Before carrying out molecular docking experiments, 
CDK2, CDK4 and CDK6 X‑ray resolved crystal structures were downloaded from the pro-
tein data bank (www.rcsb.org). Hydrogen atoms were added and their co-crystal ligands 
were removed. The structures were also minimized to remove steric clashes. The cur-
cumin for docking studies was sketched using the HyperChem 8.0 tool (13) and was mini-
mized using the steepest descent algorithm. It was then docked in the crystal structure of 
CDK2 (PDB ID=2R3I), CDK4 (PDB ID= 2W96) and CDK6 (PDB ID=1XO2) proteins using the 
GOLD docking software (14). The software was developed on the genetic algorithm and 
was trained for kinases and other related proteins. For docking simulations, the active site 
of CDKs was defined around the ATP binding site with a radius of 10 Å. The best docking 
pose of curcumin was selected based on the GOLD score. Different binding poses of the 
docked curcumin were analyzed using the PyMOL software.
RESULTS AND DISCUSSION
Synthesis of curcumin
Herein, the synthesis of curcumin from acetylacetone with vanillin under variable 
reaction conditions such as solvent systems, complexing agents, temperature, time, amount 
of water scavenger was studied in detail to afford an optimized yield. Moreover, cur-
cumin was also extracted from turmeric to establish the purity of both extracted and syn-
thetic curcumin samples.
Primary ingredients required for curcumin synthesis were acetyl acetone and 4-hy-
droxy-3-methoxybenzaldehyde (vanillin) in a theoretically stoichiometric ratio (1:2). In 
curcumin synthesis, the major issue such as Knoevenagel condensation at C‑3 of acetyl 
acetone was prevented by the complexing agent boric oxide. Solvent selection was also 
regarded as an important factor to get appropriate solubility for the reactants, intermedi-
ates and products. Subsequently, the effective strength of the catalyst in basic media in 
different solvents to promote reaction was also an important parameter in curcumin syn-
thesis. Various solvents including dimethylformamide (DMF), ethyl acetate (EtOAc), 
1,4‑dioxane, acetonitrile and toluene were employed (Table I). Effective basicity of a cata-
lyst to deprotonate methyl groups of acetyl acetone in a suitable solvent is critical since a 
stronger base can deprotonate the phenolic -OH group, which results in deactivation of 
aromatic aldehyde (vanillin) required for the condensation reaction in curcumin synthesis. 
The base, n-butylamine, was found to be the most appropriate catalyst for the desired de-
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protonation of acetylacetone. Catalyst loading was performed slowly up to 40 % of acetyl-
acetone. During complex formation of diketone (acetylacetone) with the boron and forma-
tion of curcumin, water is produced. Water in reaction mixture reacts with the diketone 
complex and reduces the curcumin yield. Higher concentration of water in the reaction 
mixture hindered the chemical reaction, so anhydrous conditions were established using 
high purity solvents. The water scavenger tributyl borate was incorporated into the reac-
tion to bind water produced during the chemical reaction and prevent its reaction with the 
diketone metal complex. The amount of water scavenger had a critical role in the reaction 
system. Different ratio of (n-BuO)3B to diketone was established.
Further, the overall reaction between the diketone complex (boron complex) and al-
dehyde (vanillin) was temperature dependent. Below 40 °C, the rate of the reaction was 
slow and appropriate temperature conditions had to be maintained to get a workable yield. 
In this respect, we made efforts to optimize the reaction conditions for curcumin synthesis 
by varying the solvents with n-butylamine as catalyst and (n-BuO)3B as water scavenger at 
different temperatures (Table I). First, the reaction between acetyl acetone and vanillin (1:2 
mole ratio) was carried out at 60 °C in DMF. The complexing agent (B2O3) was added in a 
mole ratio to acetylacetone 1:1 without any water scavenger for a period of 12 h. The yield 
obtained under the mentioned reaction conditions was very low (6 %), and then no sig-
nificant improvement in yield was observed under the same reaction conditions with a 
water scavenger.
Afterwards, different solvents were utilized with different amounts of water scaven-
ger (n-BuO)3B, and catalyst n‑butylamine, time and temperature. Ethyl acetate was found 
to be an excellent solvent for curcumin synthesis, with significant improvement in yield, 
which was due to better solubility of the reactants, intermediates and products. An in-
creased amount of (n-BuO)3B improved the curcumin yield significantly. In the presence 
of acetonitrile and dioxane, almost identical yields were obtained. Using toluene as a sol-
vent, either at 60 or 80 °C, only a small amount was observed. An excellent yield was ob-
tained by using EtOAc at a temperature of 80 °C with 4:1 of (n-BuO)3B and 2:1 of B2O3 to 
acetylacetone (Table I).
Table I. Parameters of curcumin synthesis
Solvent H2O-scavenger Temperature (°C) Time (h) Yield (%)
DMF None 60 12 6
DMF (n-BuO)3B 80 12 15
EtOAc None 60 4 21
EtOAc (n-BuO)3B 60 4 43
EtOAc (n-BuO)3B 80 4 89
Dioxane (n-BuO)3B 60 12 20
MeCN (n-BuO)3B 60 12 18
Toluene (n-BuO)3B 60 12 3
Toluene (n-BuO)3B 80 12 6
390




A curcuminoid mixture (C, DMC, BDMC) from turmeric powder was extracted and 
isolated after precipitation with petroleum ether and, then identified by TLC using various 
solvent systems (Table II). The chloroform/methanol solvent system both in TLC and the 
column was selected because excellent separations of all fractions were achieved at reason-
able Rf values. All fractions of the curcuminoid mixture were then separated by column 






Toluene/ethyl acetate (95:5) 0.92 0.86 0.81
Benzene/ethyl acetate (95:5) 0.84 0.79 0.75
Dichloromethane/methanol (95:5) 0.54 0.46 0.35
Chloroform/methanol (95:5) 0.84 0.65 0.46
Fig. 1. Chromatograms obtained for: a) curcuminoids: bis‑demethoxycurcumin (BDMC), demethoxy‑ 
curcumin (DMC) and curcumin (C), b) bis‑demethoxycurcumin (BDMC), c) demethoxycurcumin 
(DMC), d) extracted curcumin (C), e) synthetic curcumin (C) and f) mobile phase.
a)                                                                              b)
c)                                                                              d)
e)                                                                              f)
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chromatography. TLC was performed for each separated fraction and a single spot was 
observed.
The curcuminoid mixture and each separated fraction were also confirmed by HPLC. 
Well resolved peaks of all three components at retention times of 2.28 (BDMC), 3.34 (DMC) 
and 4.42 min (C) were obtained, as shown in the chromatogram (Fig. 1). Synthetic cur-
cumin was also analyzed by HPLC and a single well resolved peak confirmed excellent 
purity.
Curcumin separated from turmeric powder and synthetic curcumin were then sub-
jected to the melting point, IR, MS and NMR analyses for purity confirmation. The melting 
point and IR vibration frequencies (cm–1) are presented in Table III and there was no sig-
nificant difference in the melting point and vibration frequencies of curcumin samples. 
Curcumin existed in the tautomeric form (keto and enol form, Fig. 2) and two peaks were 
obtained in the LC‑MS system, peak 2 dominating. Peak 2 corresponded to the enol form 
due to a planar structure, which is more retentive on the ODS column surface than the 
folded structure of the keto form at position C-4 of pentadiene. Base peaks at m/z 177.07 and 
177.08 (Fig. 3) were obtained for both synthetic and extracted curcumin, resp., and major 
peaks are presented in Table III. A computational approach determined that the enol form 
was more stable but this form does not influence the therapeutic properties of curcumin 
(15). 1H NMR and 13C NMR spectral data are given in Table IV. In 1H NMR, a singlet with 
a chemical shift (δ) at 3.83 ppm corresponded to two methoxy groups and a sharp singlet 
Table III. IR vibrational frequencies, major fragments of MS and melting points of curcumin
Synthetic curcumin (m.p. = 181–182 °C) Extracted curcumin (m.p. = 182–183 °C)
υ (cm–1) υ (cm–1)
3500.01, 2846.51, 1625.97, 1600.45, 1505.09, 1426.09, 
1274.41, 1230.46, 1202.11, 1151.08,1112.81,1026.33, 
983.82, 958.29, 884.57, 854.79, 806.67, 782.51, 
713.04
3507.94, 2846.47, 1625.74, 1600.66, 1506.19, 1427.09, 
1274.71, 1231.76, 1202.71, 1151.18,1112.81,1026.04, 
983.82, 960.39, 884.57, 854.79, 808.07, 782.51, 
713.04
m/z (%) m/z (%)
51 (7.5), 77 (12.2), 89 (16.1), 91 (10), 117 (15.7), 131 
(17.4), 135 (13.1), 137 (38.8), 145 (32.3), 147 (18.0), 
149 (12.4), 150 (28.3), 175 (10.7), 177 (100), 190 
(41.4), 191 (33.2), 217 (15.6), 232 (14.0), 272 (15.7), 
350 (34.1), 368 (36.9)
51 (7.5), 77 (12.3), 89 (16.1), 91 (10), 117 (15.8), 131 
(17.4), 135 (13.1), 137 (38.8), 145 (32.3), 147 (18.0), 
149 (12.3), 150 (28.3), 175 (10.8), 177 (100), 190 
(41.3), 191 (33.2), 217 (15.6), 232 (14.0), 272 (15.7), 
350 (34.1), 368 (36.9)
Fig. 2. Keto‑enol tautomerism of curcumin.
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at δ 9.73 ppm indicated the hydroxyl group, while in 13C NMR δ at 55.8 ppm corresponded 
to the methoxy group (Fig. 3). A broad singlet at 16.41 ppm corresponded to the enolic 
hydroxyl proton. This enolic proton was equally shared by two O-atoms of the keto-enolic 
Fig. 3. Mass spectra and: a) 13C NMR, b) 1H NMR of curcumin in DMSO‑d6.
Table IV. 1H NMR and 13C NMR spectral data (δ, ppm) of curcumin
Synthetic curcumin Extracted curcumin
1H NMR 13C NMR 1H NMR 13C NMR
H Integrals C Integrals H Integrals C Integrals
1 6.07 (s, 1H) 1 101.0 1 5.98 (s, 1H) 1 100.9
2-OH 16.41 (d, 1H) 2, 2’ 183.4 2-OH 16.41 (d, 1H) 2, 2’ 183.4
3, 3’ 6.75 (d, 2H, J = 16a) 3, 3’ 121.2 3, 3’ 6.73 (d, 2H, J = 16) 3, 3’ 121.1
4, 4’ 7.54 (d, 2H, J = 16) 4, 4’ 140.9 4, 4’ 7.53 (d, 2H, J = 16) 4, 4’ 140.7
5, 5’ – 5, 5’ 126.5 5, 5’ – 5, 5’ 126.4
6, 6’ 7.31 (d, J = 2) 6, 6’ 111.3 6, 6’ 7.32 (d, J = 2) 6, 6’ 111.4
7, 7’ – 7, 7’ 148.1 7, 7’ – 7, 7’ 148.0
8, 8’-OH 9.73 (s) 8, 8’ 149.4 8, 8’-OH 9.74 (s) 8, 8’ 149.4
9, 9’ 6.85 (d, J = 8.1) 9, 9’ 115.8 9,9’ 6.85 (d, J = 8.1) 9, 9’ 115.7
10, 10’ 7.15 (dd, J = 2, 8.1) 10, 10’ 123.3 10,10’ 7.16 (dd, J = 2, 8.1) 10, 10’ 123.2
OMe 3.83 (s, 3H) OMe 55.8 OMe 3.84 (3H, s) OMe 55.7
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structure and was strongly deshielded due to involvement in the H‑bond. Enolic and keto 
carbons are undistinguishable and equivalent, showing the δ value at 183.4 ppm in 13C 
NMR. Two double bonds and aromatic rings are completely equivalent. Thus, NMR stud-
ies further provided justification that the enolic form is the more stable and prominent 
form of curcumin. The extracted curcumin had the same purity level, but a time consum-
ing procedure is required to get a reasonable yield, because curcuminoids are precipitated 
first and then curcumin is separated from the mixture. Hence, from the economical point 
of view, synthetic curcumin is more feasible than extracted curcumin with an excellent 
yield (89 %) and purity (99.8 %).
Docking with cyclin dependent kinase
Curcumin was docked in the CDK2 and CDK4 and CDK6 X‑ray structures using the 
GOLD software with all its parameters set to default. It was observed that curcumin did 
not dock well at the binding site of ATP in CDK2, CDK4 and CDK6 because a typical kinase 
inhibitor-binding pose was absent. The docking pose of curcumin in CDK4 is shown in 
Fig. 4. This pose shows two weak polar interactions between the carbonyl group of the 
curcumin and the backbone NH of Val96 and the delta nitrogen of imidazole side chain in 
His95. The present study shows that curcumin does not inhibit the CDK pathway in cancer 
and may target cancer growth via some other pathways. Based on these docking studies, 
it may be suggested that there is a need to design new curcumin derivatives with better 
potency and specificity for CDKs.
CONCLUSIONS
A rapid and concise method for the synthesis of curcumin with excellent yield (89 %) 
and purity (99.8 %) was developed. The extracted curcumin had the same purity level. 
Fig. 4. Molecular docking of curcumin with CDK4 in an active state.
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However, to get a workable yield, a time consuming procedure is required to separate 
curcumin from the curcuminoid mixture. Thus, from the economical point of view, syn-
thetic curcumin is more feasible than the extracted one.
Although there is a weak interaction between curcumin and a potential cancer target 
CDK4, the docking studies carried out in the present work suggest that it may not directly 
inhibit the CDK pathways but can control cancer by targeting other pathways. It may be 
suggested that there is a need to design new curcumin derivatives with better potency and 
specificity for CDKs.
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